A two-step kinetic enzyme-linked immunosorbent assay was developed to detect the presence of flunixin in the urine of greyhound dogs. The assay system was developed using polyclonal antiflunixin antisera, a rabbit albumin-flunixin conjugate adsorbed onto polystyrene microtiter strips, and flunixin reference standards for calibration. The assay parameters were optimized and the performance characteristics were determined. The quantitative intra-and inter-run precisions (%CV) of the analysis of replicate (n --10) flunixin-spiked urine samples were 9.9-12.5% and 10.2-13.6%, respectively. The linear dynamic range was 1-100 ng/mL, and the quantitative accuracy, as determined by calculation of percent error of measured flunixin in flunixin-spiked drug-free greyhound urine, was -16% to +14% over this range. The 150 of the ELISA was 17.3 ng/mL. The limit of detection was 25 ng/mL in greyhound urine. The reactivity in the assay system relative to flunixin (100%) was 147% for flunixin glucuronide, 25% for clonixin, and 5% for niflumic acid. The ELISA was capable of detecting total flunixin for up to 72 h in dogs administered flunixin at 0.55 mg/kg orally and up to 96 h in a dog that was administered flunixin at 1.0 mg/kg orally.
Introduction
Flunixin [2-(2'-methyl-3'-trifluoromethylanilino) nicotinic acid] (Figure 1 ) decreases prostaglandin synthesis through its inhibitory effect on cyclo-oxygenase (1) . This results in flunixin's analgesic and anti-inflammatory pharmacological response in mammals (2) . Flunixin is used to treat septic peritonitis in dogs (3) and colic (4), lameness (5) , and endotoxemia in horses (6) . This drug has been shown to exhibit potent pharmacological activity at low plasma and urinary drug concentrations in horses (7) . The pharmacokinetics of flunixin have been investigated in mixed-breed dogs and in horses (7, 8) . These studies showed that the drug was rapidly and almost completely absorbed after oral administration. The drug has a half-life of 2.5-4.9 h in dogs and 0.6-4.2 h in horses (7, 8) . These are very short half-lives for a drug that may exhibit pharmacological effects for up to 30 h following a single dose in the horse (9) .
Interest in this drug within racing jurisdictions has been attributed to its increased use in racing animals, which is thought to be related to its high potency and relatively short half-life when compared with phenylbutazone (10) . This results in a lower effective dose with relatively rapid clearance from blood and urine, making detection difficult using classical drug screening techniques such as thin-layer chromatography (TLC). The use of diuretics like furosemide concomitantly with flunixin has been shown to exacerbate this postdosing detection problem in horses (10) . Chemical methods that have been used to detect or quantitate flunixin or both in race animals include TLC (11) , high-performance liquid chromatography (HPLC) (12) , gas chromatography (GC) (13) , and gas chromatography-mass spectrometry (GC-MS) (14) . The development of this immunoassay was intended to improve the detectability of flunixin postadministration in the urine of greyhounds.
The enzyme-linked immunosorbent assay (ELISA) technique was originally described by Engvall and Perlman (15) and refers to a diverse group of heterogeneous solid-phase immunoassays. It can be used for the detection or quantitation or both of antibody or antigen/hapten. ELISA was introduced into clinical medicine as a rapid, sensitive, nonisotopic, and easy-to-perform technique for detecting many different substances, including drugs, in bodily fluids (16) . Detection of a drug by immunoassay in the urine of a race animal must be confirmed by a more specific method such as GC-MS. This study describes the development, characterization, and evaluation of a twostep competitive kinetic ELISA (k-ELISA) system (17) . NAN3, Na2CO3, KH2PO4, rabbit albumin, niflumic acid, keyhole limpet hemocyanin, 0.01M phosphate buffered saline (PBS, pH 7.4), and 0.01M PBS containing 0.05% (w/v) "l~veen 20 (PBS-T). Chemicals obtained from Fisher Scientific (Pittsburgh, PA) were reagent grade, and they included Na2HPO4, KC1, NaHC03, and H3PO4 (HPLC grade). Triethylamine (TEA) was obtained from Eastman Kodak (Rochester, NY). The TEA was purified for HPLC as described previously by Hill et al. (18) . Goat anti-rabbit IgG (heavy and light chain-specific) conjugated with horseradish peroxidase (IgG-HRPOase) was obtained from Vector Laboratories (Burlingame, CA). The ELISA substrate/chromogen reagent, TMBlue | which is a stabilized solution of hydrogen peroxide and tetramethylbenzidene (TMB), was obtained from Transgenic Sciences (Worcester, MA). Flunixin, as the meglumine salt, and clonixin were gifts from Schering Corp. (Union, NJ). Flunixin meglumine paste (Banamine| which was used in the greyhound administration studies, was obtained from Schering Corp. Flunixin glucuronide was isolated from the urine of a greyhound that was administered flunixin. The structure of the metabolite was verified by ultraviolet and mass spectrometric analyses (19) .
Materials
A keyhole limpet hemocyanin-flunixin conjugate (KLH-F) was prepared for rabbit immunizations using the N-hydroxysuccinimide ester method (20) . A rabbit albumin-flunixin conjugate (RA-F) was prepared by the same conjugation method for use as the solid-phase coating antigen for the microtiter strips in the ELISA.
Immulon 1 microtiter strips used in the ELISA were obtained from Dynatech Laboratories (Chantilly, VA). These strips were coated with 100 I~L/well of 1.0 lJg/mL RA-F conjugate in 0.05M carbonate buffer (pH 9.6) (20), covered tightly with parafilm, and allowed to incubate overnight (16-18 h ) at 4~ The wells were emptied and washed three times with PBS-T and once with distilled water. After drying with a low temperature air blower (34~ + 2~ the strips were stored in a dessicated Zip-Loc | plastic bag for future use.
Adjuvants used in antibody production included Freund's complete and incomplete adjuvant from GIBCO (Grand Island, NY). Reagent reservoirs for ELISA were obtained from COSTAR Corp. (Cambridge, MA). Dessicant packs for ELISA strip storage were obtained from Sigma Chemical.
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Animals
One-year-old female New Zealand White rabbits were used for production of polyclonal antisera to flunixin. They were obtained from Millbrook Farm (Amherst, MA). The rabbits were housed in the Pathobiology Department vivarium at the University of Connecticut.
Four greyhounds were used in the flunixin administration studies. These dogs were housed in the Diagnostic Veterinary Laboratory at Iowa State University (Ames, Iowa). All animal use had prior approval by Animal Use and Care Committees at the respective institutions.
Instrumentation
The absorbance of the ELISA reaction products was measured on a Bio-Tek model EL 312e microtiter plate reader (Bio-Tek Instruments, Winooski, VT). Data were collected on a computer and were analyzed using the Bio-Tek KinetiCalc | software and Microsoft EXCEL | spreadsheet and graphing software.
HPLC analyses were performed by gradient elution on a Hewlett-Packard (Palo Alto, CA) HP1090 with an HP1040 diode array detector (HPLC-DAD). Solvent A was 0.15M phosphoric acid and 0.05M TEA in water; solvent B was 0.15M phosphoric acid, 0.05M TEA, and 20% water in acetonitrile. The flow rate was 2.0 mL/min. The detector was set to collect ultraviolet (UV) spectral data from 195 to 405 nm at 640 ms intervals. For free flunixin and flunixin metabolite, the chromatogram was reconstructed at 327 nm. In the gradient elution program, the solvent composition was held at 100% solvent A for 2.2 rain and then changed linearly to 100% solvent B in 20 min. The column was a C8 Zorbax Rx column (4.6 mm x 25 cm) (Mac-Mod Analytical, Chadds Ford, PA) packed with 5-1Jm (nominal diameter) spherical particles. The column temperature was held at 30~ Ten microliters of sample were injected onto the column by the HP1090 autosampler.
A Fisher Scientific microtiter plate rotator was used to mix microtiter strip well contents (210 rpm) after substrate addition. 
Methods
Polyclonal antiflunixin antisera were produced by immunizing three 1-year-old female New Zealand White rabbits with KLH-F (20) . Antisera that were reactive with flunixin were detected using an RA-F-coated microtiter strip antibody detection system. Serial dilutions of antisera diluted in PBS-T were incubated for I h at room temperature in RA-F-coated microtiter strips. After emptying and washing the wells with PBS-T, well-bound antibodies were detected by incubation with goat antirabbit IgG-HRPOase with subsequent addition of the substrate/chromogen solution TMBlue. The development of a blue color (oxidized TMB) indicated peroxidase activity and, therefore, binding of second antibody to well-bound primary antibody.
The ELISA protocol consisted of pipetting 20 1JL of each flunixin standard (0.0, 1.0, 5.0, 10, 25, 50, and 100 ng/mL) prepared in PBS containing 0.02% (w/v) NaN3 (PBS-NaN3) in triplicate into the RA-F-coated microtiter strip wells. A flunixin standard containing 100,000 ng/mL flunixin was used to assess nonspecific binding. Urine samples were diluted 1:5 with PBS-NaN3 before analysis. One hundred microliters of rabbit antisera, diluted 1:4000 with PBS-T containing 0.02% (w/v) NaN 3 (PBS-T-NaN3), was added to all wells except well A1, which was the reference well. The microtiter strip well contents were mixed manually for 10 s by a mild rotary and back-andforth motion, cove.red with parafilm, and allowed to incubate at room temperature for 30 min. The wells were emptied and washed three times with PBS-T. One hundred and twenty microliters of a 1:1000 dilution of IgG-HRPOase in PBS-T (1.0 IJg/mL conjugate) was added to each well (except A1), and the wells were allowed to incubate for 30 min at room temperature. The wells were emptied and washed three times with PBS-T. The substrate/chromogen solution TMBIue (150 IJL) was added to each well, including A1. The plate was mixed for 2 min on a rotary plate mixer at 210 rpm. The absorbance of each well was measured at 650 nm every 20 s for 2 min with continuous mixing of well contents by the plate reader between readings. The Kineti-Calc software reduced the triplicate reaction rate measurements to mean milliAbsorbance per minute (mAbs/min) rates for each standard, control, and test sample. The mean rates of the standards, which were corrected for nonspecific binding, were used to calculate percent bound (%B/Bo) values and to construct a standard curve using the four-parameter logistic method of Rodbard (21) . Unknowns were calculated from the standard curve equation and corrected for pre-assay dilution.
Precision of the ELISA was assessed by determining the intra-and interassay variability of drug-free greyhound urine spiked with three concentrations of flunixin (25, 50 , and 100 ng/mL). In all cases, the added flunixin solution made up no more than 10% (by volume) of the final volume in order to preserve the urine matrix. The spiked samples were placed randomly (by lottery) in wells across the plate and assayed 10 times each on the same ELISA plate of coated strips in order to assess intra-assay variability. Interassay variability was assessed by testing the spiked urine samples in the same manner on five different days. The results obtained were analyzed statistically by calculating and comparing the mean, standard deviation, and coefficient of variation for each spiked urine set.
The analytical accuracy of the ELISA was determined by analyzing multiple (n = 5) drug-free greyhound urine samples 
the mean measured concentration and the actual concentration at each spiked urine concentration. The percent (relative) error was calculated by dividing the absolute error of each sample by its respective actual concentration and multiplying by 100.
The dynamic range of the assay was determined by analyzing flunixin standards in PBS-NaN 3 with concentrations of 0.0, 1.0, 5.0, 10, 25, 50, 100, and 500 ng/mL. Standard concentrations were plotted versus their percent bound values using the four-parameter logistic method.
The concentration of flunixin that resulted in 50% inhibition of binding (I50) on the ELISA standard curve was determined by calculating the mean Is0 from eight representative standard curves.
The limit of detection (LOD) of the assay system was determined by a statistical method (22,2:]) and an empirical method (23) . The statistical LOD was evaluated by assaying, in triplicate, 18 drug-free greyhound urine samples in the ELISA system. The apparent flunixin concentration of each sample was determined from the flunixin standard calibration curve. The detection limit was calculated as the mean of these 18 samples plus :3 standard deviations. The empirical method for determining the assay LOD was performed by assaying drugfree greyhound urine along with urine spiked with increasing amounts of flunixin. Drug-free greyhound urine was spiked to give flunixin concentrations of 5, 10, 25, 50, and 100 ng/mL and then analyzed by ELISA. The mean and standard deviation were determined for each set of measured values (n = 10). The Student's t-test (24) was employed to determine the lowest concentration of flunixin in spiked urine that could be statistically distinguished (at p < 0.05) from the assay values obtained from drug-free urine.
The determination of the crossreactivity of flunixin glucuronide, clonixin, and niflumic acid relative to flunixin in the ELISA was accomplished by preparing a series of standard solutions of these compounds in PBS-NaN 3 and assaying them in the ELISA using a flunixin calibration curve. Similar crossreactivity studies were conducted in order to determine if crossreactivity with the structurally related fenamates (e.g., flufenamic, meclofenamic, and mefenamic acids), nicotinic acid, nicotinamide, and a structurally diverse group of drugs that may be encountered in racing animals existed in the ELISA (Table I) . Flunixin, in the form of flunixin meglumine paste (Banamine), was administered orally to four greyhounds. Two of the dogs were dosed at 0.55 mg/kg, and the other two were dosed at 1.0 mg/kg. Pre-administration urine samples were collected (0-h urine) along with urine samples at 2, 4, 8, 24, 48, and 72 h for both dosing regimens. One additional 96-h sample was collected from the 1.0-mg/kg dose dogs. These urine samples were stored frozen before analysis. The frozen urine samples from the administration studies were thawed, mixed, and centrifuged. Aliquots of each urine sample were diluted 1:5, 1:10, 1:50, 1:100, ]:500, and 1:1000 with PBS-NaN3. These diluted samples were assayed according to the described ELISA protocol. The dilution with a value closest to the assay Is0 was used to calculate the concentration of"flunixin equivalents" in each sample. A flunixin equivalent is the apparent total flunixin concentration (i.e., free flunixin and flunixin metabolites collectively) in a urine sample as determined from the flunixin standard curve equation.
Urine samples from the administration studies were also assayed for free flunixin and total flunixin (free plus conjugated flunixin) by extraction, before and after base hydrolysis, followed by HPLC analysis. Flunixin in the urine samples was extracted into chloroform at pH 4.7 with and without prior treatment with strong base (1.6M NaOH at room temperature for 30 rain). Flunixin standards (0.0, 0.1, 0.5, 1.0, 5.0, and 10.0 pg/mL in water) were prepared and assayed in the same manner (without base hydrolysis). An internal standard (1 mL of 1-pg/mL clonixin in water) was added to all samples before the extraction. The chloroform extracts were evaporated to dryness in a waterbath at 65~ under a stream of nitrogen. The residues were dissolved in 0.1 mL methanol and analyzed by the HPLC-DAD system. A linear regression line was calculated from the peak-area ratios of the standards and the internal standard obtained from the chromatogram. The flunixin concentration in each sample was calculated from the linear regression equation. Figure 2 shows a representative ELISA calibration curve from the optimized ELISA protocol. The data indicated that the linear dynamic range was approximately 1-100 ng/mL. The ELISA Is0 was determined to be 17.3 ng/mL from the mean I50 value of eight representative standard curves (s = 2.4). The intra-assay precision of the ELISA varied from 9.9 to 12.5% coefficient of variation (%CV), and the interassay precision varied from 10.2 to 13.6 %CV (Table II) . The analytical accuracy of the ELISA, expressed as percent error, ranged from -16% to +14% over the linear dynamic range of the assay (Table III) . The LOD of this ELISA, as determined by the statistical method, showed that the 18 drug-free greyhound urines assayed in triplicate in the ELISA system gave a mean percent binding of 103% with a standard deviation of 4%. A threestandard-deviation response would equal 91% bound. This corresponds to 1 ng/mL flunixin in the assayed samples ( Figure  2 ) and 5 ng/mL in the original samples. Table IV lists for the empirical method of determining limit of detection. At p < 0.05, the limit of detection for flunixin in the ELISA system was determined to be 25 ng/mL (0.025 pg/mL) in greyhound urine. Table V lists the relative reactivities (% crossreactivity) of flunixin, flunixin glucuronide, clonixin, and niflumic acid in the ELISA. Table I lists a structurally diverse group of drugs that may be encountered in racing animals. All of these drugs tested negative (crossreactivity, < 0.01%) in the ELISA at a concentration of 100 pg/mL in PBS-NaN3. Figure 3 shows a representative urinary excretion profile of flunixin as assayed by HPLC and ELISA in the pre-and postadministration greyhound urine samples from one of the dogs dosed at 0.55 mg/kg body weight. The HPLC analysis detected free and total flunixin in the urine samples. The ELISA detected total flunixin (free flunixin plus metabolites) in greyhound urine as flunixin equivalents. The ELISA was capable of detecting flunixin equivalents for up to 72-h postdosing, whereas HPLC was able to detect total flunixin for up to 48oh postadministration at this dose. The second greyhound dosed at 0.55 mg/kg showed a similar temporal detection pattern by HPLC (up to 48 h) and by ELISA (up to 72 h). Figure 4 shows the urinary excretion profile of flunixin as analyzed by HPLC and ELISA in the pre-and postadministration greyhound urine samples from one of the dogs dosed at 1.0 mg/kg body weight. The data indicated that the ELISA was capable of detecting flunixin equivalents in this greyhound urine for up to 96-h postadministration, whereas HPLC was able to detect total flunixin for up to 48 h at this dose. Urine samples from the second greyhound dosed at 1.0 mg/kg showed detection of total flunixin up to 48-h postadministration by HPLC and to 72 h by ELISA.
Results
Discussion
In the development of an immunoassay for a drug or its major metabolite(s) or both, the specific reactivity of the primary antibody in the assay system is of paramount importance. The antisera produced and selected for this ELISA demonstrated high reactivity with the parent compound flunixin and showed enhanced reactivity with flunixin glucuronide. In addition, the flunixin analogues clonixin and niflumic acid showed some crossreactivity with the antibody (Table V) . A diverse group of drugs (Table I ) that may be encountered in racing animals showed no reactivity with the anti-sera in the ELISA. Therefore, the selected antisera exhibited good specificity for the compounds of interest with little or no crossreactivity with other compounds.
The two-step ELISA format was selected for this study for several analytical and practical considerations. The two-step method, in which antigen is adsorbed onto the microtiter strip wells, does not allow contact between the biological sample and the enzyme label at any time. This serves to prevent possible inhibition of enzyme activity by inhibitors that may be present in the dog urine (25) . The two-step method does not necessitate preparation of a drug-enzyme conjugate as does the one-step ELISA method (antibody-coated wells). In additiona, the second antibody in the two-step method may be labeled with multiple enzyme molecules, which may further amplify the detection system and enhance sensitivity. Finally, the enzyme- labeled second antibody is commercially available and may be used in many different assay systems, assuming that the primary antibody is from the same species. Greyhound urine contains primarily flunixin glucuronide and free flunixin, in varying concentrations, in timed samples postadministration ( Figures 3A and 4A) (19) . In order to determine the usefulness of the developed ELISA for detecting flunixin in greyhound urine, it was compared with a quantitative protocol involving base hydrolysis of conjugates and acid extraction of free flunixin into chloroform followed by HFLC. The results of the temporal urinary excretion profiles by ELISA showed the ability of the ELISA to detect flunixin in greyhound urine for up to 72-h after a 0.55-mg/kg dose ( Figure 3B ). In greyhounds that were administered 1.0 mg/kg flunixin, the ELISA detected total flunixin up to 96-h postadministration in one dog ( Figure 4B ) and up to 72-h postdose in urine from a second dog. In comparison, the quantitative extraction/HPLC method was able to detect total flunixin for up to 48 h in the urine of all four dogs at both dosing regimens ( Figures 3A and 4A ). The data suggested that the developed ELISA was able to detect total flunixin in the urine of greyhounds, as flunixin equivalents, for a longer time postadministration than HPLC. This may be due to the enhanced reactivity of the ELISA for flunixin glucuronide and to its ability to detect lower concentrations of total flunixin than the HPLC method. 
Conclusion
The development of an ELISA system capable of detecting flunixin in the urine of greyhounds postadministration was the primary purpose of this study. The performance characteristics of this ELISA system showed that it exhibited a 100-fold dynamic range, moderate intra-and interrun precision, good analytical accuracy, and good specificity for flunixin and flunixin glucuronide. This ELISA system allows for the detection of flunixin in greyhound urine with an analysis time of less than 2 h with no sample pretreatment and with a detection limit of 25 ng/mL.
